Amgen/$AMGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Ticker
$AMGN
Sector
Primary listing
Employees
31,500
Headquarters
Website
Amgen Metrics
BasicAdvanced
$195bn
25.20
$14.37
0.44
$9.80
2.78%
Price and volume
Market cap
$195bn
Beta
0.44
52-week high
$391.29
52-week low
$269.77
Average daily volume
2.9m
Dividend rate
$9.80
Financial strength
Current ratio
1.261
Quick ratio
0.849
Long term debt to equity
564.592
Total debt to equity
623.754
Dividend payout ratio (TTM)
66.97%
Interest coverage (TTM)
3.92%
Profitability
EBITDA (TTM)
17,186.75
Gross margin (TTM)
71.44%
Net profit margin (TTM)
20.96%
Operating margin (TTM)
32.63%
Effective tax rate (TTM)
14.16%
Revenue per employee (TTM)
$1,180,000
Management effectiveness
Return on assets (TTM)
8.35%
Return on equity (TTM)
101.32%
Valuation
Price to earnings (TTM)
25.203
Price to revenue (TTM)
5.239
Price to book
21.28
Price to tangible book (TTM)
-6.33
Price to free cash flow (TTM)
22.683
Free cash flow yield (TTM)
4.41%
Free cash flow per share (TTM)
15.965
Dividend yield (TTM)
2.71%
Forward dividend yield
2.78%
Growth
Revenue change (TTM)
9.07%
Earnings per share change (TTM)
31.30%
3-year revenue growth (CAGR)
12.43%
10-year revenue growth (CAGR)
5.32%
3-year earnings per share growth (CAGR)
-0.80%
10-year earnings per share growth (CAGR)
4.28%
3-year dividend per share growth (CAGR)
6.71%
10-year dividend per share growth (CAGR)
11.11%
What the Analysts think about Amgen
Analyst ratings (Buy, Hold, Sell) for Amgen stock.
Amgen Financial Performance
Revenues and expenses
Amgen Earnings Performance
Company profitability
Amgen News
AllArticlesVideos
Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel
Reuters·1 hour ago
Medical journal retracts paper on Amgen's Tavneos drug trial after FDA findings
Reuters·2 days ago
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease
Benzinga·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs